GAMIDA CELL INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: GDA-201

First Posted Date: 2022-03-25

Last Posted Date: 2024-05-02

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 13

Registration Number: NCT05296525

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital, New York, New York, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States

and more 3 locations

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Phase 3

Active, not recruiting

Conditions: Hematological Malignancies

Interventions: Biological: omidubicel

First Posted Date: 2020-02-07

Last Posted Date: 2024-12-27

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 36

Registration Number: NCT04260698

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 3 locations

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3

Active, not recruiting

Conditions: Hematological Malignancies
Acute Lymphoblastic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Lymphoma
Chronic Myelogenous Leukemia (CML)
Acute Leukemia

Interventions: Drug: NiCord® (omidubicel)
Other: Cord Blood Unit

First Posted Date: 2016-04-06

Last Posted Date: 2024-10-08

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 125

Registration Number: NCT02730299

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇫🇷
Robert Debré, Paris, France

and more 49 locations

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

Phase 1

Terminated

Conditions: Thalassemia
Sickle Cell Disease

Interventions: Biological: CordIn

First Posted Date: 2015-07-22

Last Posted Date: 2019-06-26

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 1

Registration Number: NCT02504619

Locations: 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸
Children's National, Washington, District of Columbia, United States
🇫🇷
Hôpital Robert Debré, Paris, France

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Completed

Conditions: Patients Transplanted With NiCord/CordIn (Omidubicel)

Interventions: Genetic: NiCord®/CordIn™ (omidubicel)

First Posted Date: 2014-01-17

Last Posted Date: 2024-10-23

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 33

Registration Number: NCT02039557

Locations: 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇪🇸
University Hospital Vall D'Hebron, Barcelona, Spain
🇪🇸
Hospital Universitario La Fe, Valencia, Spain

and more 6 locations

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

Phase 1

Completed

Conditions: Hematological Malignancies
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)

Interventions: Drug: NiCord®

First Posted Date: 2013-03-22

Last Posted Date: 2020-10-22

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 36

Registration Number: NCT01816230

Locations: 🇪🇸
University Hospital Vall d´Hebron, Barcelona, Spain
🇺🇸
Steven and Alexandra Cohen Children's Medical Center, New York, New York, United States
🇮🇹
University of Turin, Turin, Italy

and more 12 locations

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Phase 1

Completed

Conditions: Sickle Cell Disease & Thalassemia

Interventions: Drug: NiCord

First Posted Date: 2012-05-03

Last Posted Date: 2022-05-20

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 16

Registration Number: NCT01590628

Locations: 🇺🇸
The University Of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Steven & Alexandra Cohen Children's Medical Center, New York, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia (AML)
Non-Hodgkin's Lymphoma
Hodgkin's Disease
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndrome (MDS)

Interventions: Drug: NiCord®

First Posted Date: 2010-10-15

Last Posted Date: 2021-08-03

Lead Sponsor: Gamida Cell ltd

Target Recruit Count: 12

Registration Number: NCT01221857

Locations: 🇺🇸
Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy